Clinical trial · Observational
Research Collaboration for a Precision Oncology Program (POP)
NCT06680726CI-TRIAL-00082379POPrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Precision Oncology Program (POP) research collaboration aims to help generate information about the individual tumour biology for patients with advanced malignancies, using innovative biotechnologies and patient profile comparison ("matching") against specific databases (Real-world data, RWD) and to inform about potential benefit, or lack of benefit, from a given treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Imaging Mass Cytometry | Other | — | UNRESOLVED |
| Matching with RWD | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Utility of RWD matching report as assessed by the questionnaire
- timeFrame
- From date of enrollment, assessed up to 2 years
- description
- 1. Is the Report used to identify imminent or future treatment options? 2. How has the Report changed your confidence in the primary decision? 3. Does the Report support the primary therapy decision? 4. Is the relevant information in the Report non supportive of the Resources used or the primary therapy decision? 5. What Resources did you use for the primary therapy decision? 6. How useful was the Report to decide on the secondary therapy decision? 7. Which features of the Report were used for the secondary therapy decision? 8. Could you have gathered the information in the Report used for the secondary treatment decision in less than 15 min? 9. Did the Report provide unique information on personalizing future treatment regimens?
- measure
- Utility of the IMC report as assessed by the questionnaire
- timeFrame
- From date of enrollment, assessed up to 2 years
- description
- 1. Is the Report used to identify imminent or future treatment options? 2. How has the Report changed your confidence in the primary decision? 3. Does the Report support the primary therapy decision? 4. Is the relevant information in the Report non supportive of the Resources used or the primary therapy decision? 5. What Resources did you use for the primary therapy decision? 6. How useful was the Report to decide on the secondary therapy decision? 7. Which features of the Report were used for the secondary therapy decision? 8. Could you have gathered the information in the Report used for the secondary treatment decision in less than 15 min? 9. Did the Report provide unique information on personalizing future treatment regimens?
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Signed informed consent * In the case of deceased persons: signed general consent * All patients with the diagnosis of a solid tumour including adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, sarcoma, etc * ECOG-performance status 0-2, if applicable * Willing and able to understand all project related procedures, including transfer of coded (i.e. pseudonymised) or anonymized clinical data to external partners (e.g. Roche), if applicable Exclusion Criteria: * Patients with the diagnosis of blood cancer.
References
Publications (1)
- DERIVEDBoos LA, Doerig C, Gut G, Miglino N, Fabregas Ibanez L, Rizzo S, Scharfe Fruechtenicht C, Chitale N, Lu C, Zoche M, Bodenmiller B, Chevrier S, Eklund AS, Nowak M, Rahmani Khajouei S, Berardo CG, Kaczmarek L, Bosshard K, Archey W, Bodmer M, Glinz D, Camarillo-Retamosa E, Hempel CL, Rahimzadeh P, Gosztonyi B, Richter U, Bankel L, Wicki A. Precision Oncology Program (POP), an observational study using real-world data and imaging mass cytometry to explore decision support for the Molecular Tumor Board: study protocol. BMJ Open. 2025 Mar 26;15(3):e096591. doi: 10.1136/bmjopen-2024-096591. PMID 40139698